Melatonin

Generic Name: Melatonin

Brand Names: Circadin, Slenyto, Melatonin Neurim

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₂O_₂

CAS Number: 73-31-4

Unique Ingredient Identifier: JL5DK93RCL

Background: Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence ...

Indication: Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for ...

Associated Conditions: Insomnia

Associated Therapies: -

Clinical Trials

Preoperative Melatonin or Vitamin C Administration on Postoperative Analgesia

Phase 4

Completed

Conditions: Postoperative Pain

Interventions: Drug: Melatonin
Drug: Vitamin C
Other: Placebo

First Posted Date: 2015-12-24

Last Posted Date: 2021-08-09

Lead Sponsor: Cukurova University

Target Recruit Count: 55

Registration Number: NCT02639741

Locations: 🇹🇷
Hakkı Ünlügenç, Adana, Turkey

Effects of Melatonin Supplementation on Renal Physiology in a Habitual Sleep Restricted Population.

Phase 2

Terminated

Conditions: Prediabetic State
Obesity

Interventions: Drug: Placebo
Drug: Melatonin

First Posted Date: 2015-12-16

Last Posted Date: 2021-06-30

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 12

Registration Number: NCT02631148

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia

Early Phase 1

Recruiting

Conditions: Hypoxic Ischemic Encephalopathy

Interventions: Drug: Melatonin
Other: Magnetic Resonance Imaging
Other: Pharmacokinetics
Behavioral: Neurological Outcome Assessment

First Posted Date: 2015-12-04

Last Posted Date: 2024-08-21

Lead Sponsor: University of Florida

Target Recruit Count: 70

Registration Number: NCT02621944

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Florida Hospital for Children, Orlando, Florida, United States

Melatonin for Prevention of Delirium in Critically Ill Patients

Phase 2

Conditions: Delirium

Interventions: Drug: Placebo
Drug: Melatonin

First Posted Date: 2015-11-26

Last Posted Date: 2017-10-19

Lead Sponsor: Mount Sinai Hospital, Canada

Target Recruit Count: 69

Registration Number: NCT02615340

Locations: 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦
Hôpital du Sacré-Coeur, Montréal, Quebec, Canada
🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients

Phase 3

Completed

Conditions: Delirium

Interventions: Drug: Sugar pill
Drug: Melatonin

First Posted Date: 2015-08-31

Last Posted Date: 2021-08-26

Lead Sponsor: Fraser Health

Target Recruit Count: 19

Registration Number: NCT02536417

Locations: 🇨🇦
Surrey Memorial Hospital, Surrey, British Columbia, Canada

Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.

Phase 2

Conditions: Breast Cancer

Interventions: Drug: metformin
Drug: Fluoruracil
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: melatonin

First Posted Date: 2015-07-23

Last Posted Date: 2019-09-04

Lead Sponsor: N.N. Petrov National Medical Research Center of Oncology

Target Recruit Count: 96

Registration Number: NCT02506777

Locations: 🇷🇺
N.N. Petrov Research Institute of Oncology Clinical Diagnostic Department, Saint - Petersburg, Russian Federation

Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: metformin
Drug: Melatonin
Drug: Toremifene

First Posted Date: 2015-07-23

Last Posted Date: 2019-09-04

Lead Sponsor: N.N. Petrov National Medical Research Center of Oncology

Target Recruit Count: 96

Registration Number: NCT02506790

Locations: 🇷🇺
N.N. Petrov Research Institute of Oncology Clinical Diagnostic Department, Saint - Petersburg, Russian Federation

Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer

Phase 1

Terminated

Conditions: Quality of Life

Interventions: Biological: Reishi mushroom extract
Drug: Coenzyme Q10
Drug: Melatonin

First Posted Date: 2015-07-01

Last Posted Date: 2018-08-01

Lead Sponsor: Midwestern Regional Medical Center

Target Recruit Count: 5

Registration Number: NCT02486796

The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects

Not Applicable

Completed

Conditions: Multiple Sclerosis
Oxidative Stress

Interventions: Drug: Melatonin
Other: Hydrogen peroxide

First Posted Date: 2015-06-04

Last Posted Date: 2017-05-02

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 34

Registration Number: NCT02463318

Locations: 🇮🇷
Solaleh Emamgholipour, Tehran, Iran, Islamic Republic of

Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients

Phase 3

Terminated

Conditions: Cancer

Interventions: Drug: melatonin
Drug: placebo

First Posted Date: 2015-05-27

Last Posted Date: 2022-06-13

Lead Sponsor: Centre Jean Perrin

Target Recruit Count: 123

Registration Number: NCT02454855

Locations: 🇫🇷
Centre Hospitalier Lyon Sud, Lyon, France
🇫🇷
CHU Clermont-Ferrand, Clermont-Ferrand, France
🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy